Eli Lilly Files 8-K on Debt Instruments

Ticker: LLY · Form: 8-K · Filed: Aug 20, 2025 · CIK: 59478

Eli Lilly & Co 8-K Filing Summary
FieldDetail
CompanyEli Lilly & Co (LLY)
Form Type8-K
Filed DateAug 20, 2025
Risk Levellow
Pages5
Reading Time6 min
Key Dollar Amounts$750,000,000, $1,000,000,000, $1,250,000,000, $6.71 billion
Sentimentneutral

Sentiment: neutral

Topics: debt, financing, disclosure

Related Tickers: LLY

TL;DR

LLY filed an 8-K detailing various debt notes due between 2026 and 2061.

AI Summary

Eli Lilly and Company (LLY) filed an 8-K on August 20, 2025, reporting "Other Events" and "Financial Statements and Exhibits" as of August 18, 2025. The filing details various debt instruments, including notes due in 2026, 2030, 2031, 2033, 2036, 2043, 2049, 2051, and 2061, indicating potential financing activities or debt management. No specific dollar amounts for these notes were provided in the excerpt.

Why It Matters

This filing indicates Eli Lilly is actively managing its debt structure, which could impact its financial leverage and future borrowing costs.

Risk Assessment

Risk Level: low — The filing is a routine disclosure of debt instruments and does not appear to contain significant new risks.

Key Players & Entities

  • Eli Lilly & Co (company) — Filer
  • LLY (company) — Ticker Symbol

FAQ

What specific types of debt instruments are detailed in the filing?

The filing details various notes with different interest rates and maturity dates, including A1.625% Notes due June 2, 2026, A2.125% Notes due June 3, 2030, A6.25% Notes due 2031, A5.00% Notes due 2033, A6.77% Notes due January 1, 2036, A1.625% Notes due 2043, A1.700% Notes due 2049, A1.125% Notes due 2051, and A1.375% Notes due 2061.

What is the filing date for this 8-K?

The filing date is August 20, 2025.

What is the period of report for this 8-K?

The conformed period of report is August 18, 2025.

What are the main items reported in this 8-K filing?

The main items reported are 'Other Events' and 'Financial Statements and Exhibits'.

What is Eli Lilly's state of incorporation and fiscal year end?

Eli Lilly's state of incorporation is IN, and its fiscal year end is 1231.

Filing Stats: 1,397 words · 6 min read · ~5 pages · Grade level 7.7 · Accepted 2025-08-20 16:16:08

Key Financial Figures

  • $750,000,000 — the issuance and sale by the Company of $750,000,000 aggregate principal amount of its Float
  • $1,000,000,000 — s due 2028 (the "Floating Rate Notes"), $1,000,000,000 aggregate principal amount of its 4.000
  • $1,250,000,000 — 550% Notes due 2032 (the "2032 Notes"), $1,250,000,000 aggregate principal amount of its 4.900
  • $6.71 billion — Company, net proceeds of approximately $6.71 billion. Upon the occurrence of an Event of D

Filing Documents

Financial Statements and Exhibits

Financial Statements and Exhibits. (d)Exhibits 1.1 Underwriting Agreement, dated August 18, 2025, among Eli Lilly and Company and Citigroup Global Markets Inc., Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC, Mizuho Securities USA LLC and Morgan Stanley & Co. LLC, as representatives of the several underwriters named therein. 4.1* Indenture, dated February 1, 1991, among Eli Lilly and Company and Deutsche Bank Trust Company Americas, as successor to Citibank, N.A., as Trustee. 4.2 Tripartite Agreement, dated September 13, 2007, appointing Deutsche Bank Trust Company Americas as Successor Trustee under the Indenture listed above. 4.3 Form of Officers' Certificate setting forth the terms and form of the Fixed Rate Notes. 4.4 Form of Officers' Certificate setting forth the terms and form of the Floating Rate Notes. 4.5 Form of Floating Rate Note due 2028 (included in Exhibit 4.4 above). 4.6 Form of 4.000% Note due 2028 (included in Exhibit 4.3 above). 4.7 Form of 4.250% Note due 2031 (included in Exhibit 4.3 above). 4.8 Form of 4.550% Note due 2032 (included in Exhibit 4.3 above). 4.9 Form of 4.900% Note due 2035 (included in Exhibit 4.3 above). 4.10 Form of 5.550% Note due 2055 (included in Exhibit 4.3 above). 4.11 Form of 5.650% Note due 2065 (included in Exhibit 4.3 above). 5.1 Opinion of Kirkland & Ellis LLP. 5.2 Opinion of Jamie Burnett, Esq. 23.1 Consent of Kirkland & Ellis LLP (included as part of Exhibit 5.1). 23.2 Consent of Jamie Burnett, Esq. (included as part of Exhibit 5.2). 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). * Incorporated by reference to the same-numbered exhibit of the Company's Registration Statement on Form S-3 (File No. 333-186979), filed with the Securities and Exchange Commission ("SEC") on March 1, 2013. Incorporated by reference to the same-numbered exhibit of the Company's Annual Report on Form 10-K for the year ended Dece

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. ELI LILLY AND COMPANY (Registrant) By: /s/ Jon Haug Name: Jon Haug Title: Senior Vice President, Treasurer and Corporate Finance and Investment Banking Dated: August 20, 2025

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.